Novartis AG History

Lichtstrasse 35
CH-4002 Basel

Telephone: (41) 61-324-1111
Fax: (41) 61-324-8001

Public Company
Incorporated: 1996
Employees: 67,653
Sales: CHFr 35.80 billion ($22.21 billion) (2000)
Stock Exchanges: Zurich New York
Ticker Symbols: NVS (NYSE); NOVN (SWX)
NAIC: 325412 Pharmaceutical Preparation Manufacturing; 541710 Research and Development in the Physical, Engineering, and Life Sciences; 621511 Medical Laboratories; 541380 Testing Laboratories

Company Perspectives:

We, at Novartis, are committed to improving health and well-being through innovative products and services. We aspire to capture and hold a leadership position in all of our businesses with a strong, sustainable performance based on continuous innovation. Our long-term success is founded on meeting the expectations of all our stakeholders--our customers, our people, our shareholders and the communities in which we live and work. This is who we are. Key Dates:

Key Dates:

Alexander Clavel founds silk dyeing works in Basel, Switzerland .
Kern & Sandoz is formed.
Geigy is founded in Grenzach, Germany.
Sandoz Chemical Company Ltd. begins operations in England.
Arthur Stoll creates Pharmaceutical Department at Sandoz.
Ciba, Sandoz, and Geigy form Basel AG cartel.
Basel AG joins IG Farben to form Dual Cartel.
Geigy begins producing insecticides.
Dr. Paul Mueller discovers insecticidal properties of DDT.
Geigy launches anti-rheumatic drug Butazolidin.
Basel AG is dissolved.
Sandoz launches neuroleptic drug Melleril.
Sandoz forms research center in East Hanover, New Jersey.
Ciba and Geigy merge to form Ciba-Geigy Ltd.
Ciba-Geigy Ltd. acquires Funk Seeds International.
Ciba-Geigy Ltd. forms biotechnology unit.
Ciba-Vision is formed.
Ciba-Geigy and Sandoz merge to form Novartis AG
Novartis divests seed and crop protection holdings.

Company History:

Further Reading:

  • Buckley, Neil, 'More on Gene-Modified Food,' Financial Times (London), July 25, 1997.
  • Capell, Kerry, with Heidi Dawley, 'Healing Novartis,' Business Week, November 8, 1999.
  • Enri, Paul, The Basel Marriage: History of the Ciba-Geigy Merger, Zurich, Switzerland: Neue Zurcher Zeitung, 1979.
  • Fisher, Lawrence M., 'Two Deals Extend the Financial Frontiers of Gene Therapy,' New York Times, January 14, 1997.
  • Ford, Peter, 'Wary Europe Enters Biotech Age,' Christian Science Monitor, June 10, 1998.
  • Gebhart, Fred, 'Skin Patch Makers Fight to Be No. 1 in War on Nicotine,' Drug Topics, January 20, 1992, p. 26.
  • Graham, David E., 'Plant Genetics to Grow Here: Swiss Company Announces $600 Million Biotech Lab,' San Diego Union-Tribune, July 22, 1998.
  • Hall, William, 'Sandoz and Ciba to Sell Part of U.S. Business,' Financial Times (London), August 29, 1996.
  • Hunter, David, 'Ciba-Geigy: Back to the Roots for Renewed Growth,' Chemical Week, June 21, 1989, p. 21.
  • Kirschner, Elisabeth, 'Ciba-Geigy and New Jersey Settle Toms River Battle,' Chemical Week, March 11, 1992, p. 14.
  • Lichtenstein, William, 'The Toms River Experience,' Chemical Engineering, April 1991, p. 45.
  • McCarthy, Joseph L., 'Alex Kraurer: Ciba-Geigy,' Chief Executive, July/August 1992, p. 20.
  • Michaels, Adrian, 'Novartis Hopes New Drugs Will Boost US Sales,' Financial Times (London), February 15, 2001.
  • Morris, Gregory D., 'Ciba-Geigy Enters the $1.5 Billion/Year Corn Biotech Race,' Chemical Week, September 12, 1990, p. 12.
  • Shon, Melissa, 'Nicotine Patch Market Takes a Fall, But Why?,' Chemical Marketing Reporter, September 14, 1992, p. 5.
  • Wilsher, Peter, 'The Feeling Grows That Going Green Is Good for Business,' Management Today, October 1991, p. 27.

Source: International Directory of Company Histories, Vol. 39. St. James Press, 2001.